The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. - Wikidata - wikimedia - TriplyDB

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

http://www.wikidata.org/entity/Q37308863

about

A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment Tumor-infiltrating dendritic cells in cancer pathogenesis Targeted immune therapy of ovarian cancer The Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical Failure Minireview: Regulatory T Cells and Ovarian Cancer.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Islet cell transplant and the incorporation of Tregs.An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study.Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment.Systematic evaluation of immune regulation and modulation Current state of biomarkers in ovarian cancer prognosis.The immune system and cancer evasion strategies: therapeutic concepts.Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.New Approaches for Immune Directed Treatment for Ovarian Cancer.The Unique Molecular and Cellular Microenvironment of Ovarian Cancer The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report.miRNAs and ovarian cancer: An overview.Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype.APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria.Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization.Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment.Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

P2860

Q26751472-E4E76EBB-A62B-4CA9-AD99-DB4BBCF661B5 Q26799117-E212C1B3-86CF-4850-89A3-23B20D932508 Q26861633-F2AC948E-A9BB-410D-8AC4-AD0322286983 Q28082828-D7D1FEC6-C169-40DE-AF7E-C14F19507FB1 Q28553364-496A6E7C-97C8-4EBA-A8C1-D8E72FDC532E Q30244214-ED06722B-E579-4A9C-BB9A-D41EF0092170 Q33889105-9D866CFC-AA83-475D-ACD9-2CCC916B468D Q34729072-0AB8CE8A-AC70-4426-99D0-8C0100BF6414 Q35122843-0BA94904-23FF-4540-8CE2-79A5EFDBEB3F Q35157858-09AB7648-4C80-4469-A7E7-4BDE6BC09AD3 Q35274995-4529E7F0-B079-4CA1-83ED-5AA84F263EF6 Q35506606-367D43D7-A1F8-426A-B49F-A7F01F246876 Q35905137-C1F838ED-9A71-4768-9C4C-20CA32EAB5F6 Q36083213-90E70AC0-54C3-43FB-B21B-B69AB101F499 Q36107953-2A3A347B-E99F-4CB0-88D4-7F0D2D6E7A8D Q36256035-7054C0BD-B0BE-4BE6-8B43-72175FF26A5E Q36295211-7B8F9A24-BDE5-494B-A062-6FC0F4848872 Q36471523-A787FC75-561C-4F6D-9532-14FE35935E9E Q36498243-1FBE0E4C-D373-4128-915C-CE936A2F7E9E Q36821149-3581AD7B-3B69-493A-9264-A2544C5F00CB Q37456596-D483F3BA-FAD9-416A-869E-D1C15780C475 Q37536946-B5EAE68A-7639-4D4C-9D5F-5BE8F89CEBE0 Q37713498-C131A1F6-AEF3-4EFA-A309-F6757C65443F Q38628964-4546B4FB-9EB8-41CA-9A34-DFA782B44045 Q38691172-C8D4D1D2-66FB-4854-A2D6-3F7759D6DC22 Q38739860-76773710-8613-4F6B-AA26-AD7C3FFF2726 Q38760516-2522EF8B-E45F-4994-9459-A64C21F57143 Q39169603-E56CAD8D-A984-4186-8D87-CD12BD21FF7C Q39271605-97E3398A-AEF3-4C5A-AED5-07AA64F1BFB5 Q39432311-515B6AA8-4AE2-4678-8104-ABDACF060546 Q39863552-897D0AE8-4D0E-4921-8B62-275E6F83C11A Q39888120-0ECAAA4D-A112-48C8-BB0C-9312C3808639 Q40449413-E491A335-F0E5-4138-B541-69A1665A75BB Q41316816-B2589EAE-77A7-445C-BF70-2E2C3ED6AF32 Q41652033-48B0540B-1A2B-4A08-9D5A-42A5C48D2D3D Q41660755-78819593-76AA-49BA-8ED0-CA34AD28852E Q43924266-AB247349-A98B-4E10-A61C-93C222C89CC5 Q46540302-CE58BA27-3388-46F2-901B-13BD38FC892B Q47398937-C338F487-3858-4D98-8420-630C6309DABC Q47725386-6886FC1F-992A-400C-811A-FC5FF26B5F30

P2860

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

http://www.wikidata.org/entity/Q37308863

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@en

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@nl

type

label

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@en

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@nl

prefLabel

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@en

The ratios of CD8+ T cells to ...... n human serous ovarian cancer.

@nl

P1433

Q37308863-9409AD84-F9C9-4F44-9535-72FB9FEBECE6

P1476

Q37308863-166AD32B-3407-4A6C-8DCB-3F217A471F90

P2093

Q37308863-082A7F1D-4BE5-4E4B-B2E4-166A45C82ADF

Q37308863-2DD26ECD-5B09-4D08-AF35-41585023C3F1

Q37308863-99C2A8BF-63DE-4DE8-AB88-5C9F0AE24241

Q37308863-9C8B394C-DE45-456A-A8AE-4AA9A998771F

Q37308863-E0C69EEC-A582-4468-ACF7-34DB064BA376

Q37308863-E8ABAF31-BC90-45DB-9579-AFF941CCE615

Q37308863-F67B8D1F-834E-4CBC-8249-55ACC4646708

P2860

Q37308863-07C53DB2-E2FA-4973-886D-62F18FEEB290

Q37308863-085BC9DF-3E01-4739-AEC5-F653D66EC866

Q37308863-0CF661BF-3F43-43E8-9652-026FB49C5E98

Q37308863-1D82431C-4AD6-46EB-84DA-07BD73257A8D

Q37308863-2B198BCE-AFB0-4E7A-B86C-26D5A10B6232

Q37308863-40276BB3-F158-4474-A03F-C2B1760FB42E

Q37308863-46348727-388B-4771-AC49-61AC2725E833

Q37308863-4D4D70EE-A6C5-4EAE-846F-6F3345EF5B37

Q37308863-51A7F723-BFD6-402A-8886-1D0BCA109B39

Q37308863-574B6234-5035-4061-9FF9-3D820B9B95D4

P304

Q37308863-E4005B3D-9B5A-405E-8D2B-2D86D0023BC3

P31

Q37308863-234FA4EC-3DA7-4874-8A90-B9B2514E22D4

P356

Q37308863-AD53300E-9C08-4B56-B85B-1A739B7C9B65

P407

Q37308863-3FB4E118-4102-4C44-AED6-CA78F8FFCA6D

P433

Q37308863-69C95D68-A8A7-4B26-86E8-3A019AA676F6

P478

Q37308863-C570C7F2-0299-4512-9C6B-EF26C641EF89

P50

Q37308863-CD419969-37C4-4563-AFFC-6C5FC3CBE5B5

P577

Q37308863-96D55389-0B8C-43B8-B98A-2921EAAAA1BB

P5875

Q37308863-8CDEF2E1-491C-4844-8009-688DE9E0038A

P698

Q37308863-89BE60D6-4A83-43F7-B445-F6D4472070B3

P921

Q37308863-215F0E7D-26D4-4CA0-8874-83FB41861649

P932

Q37308863-A88BFE38-6931-4DB5-958B-F010DA6C14DB

P356

JOURNAL.PONE.0080063

P1433

P1476

The ratios of CD8+ T cells to ...... in human serous ovarian cancer

@en

P2093

Ann L Oberg

http://www.w3.org/2001/XMLSchema#string

Claudia C Preston

http://www.w3.org/2001/XMLSchema#string

Daniel W Visscher

http://www.w3.org/2001/XMLSchema#string

Ellen L Goode

http://www.w3.org/2001/XMLSchema#string

Keith L Knutson

http://www.w3.org/2001/XMLSchema#string

Kimberly R Kalli

http://www.w3.org/2001/XMLSchema#string

Lynn C Hartmann

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

Control of regulatory T cell development by the transcription factor Foxp3

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

P304

e80063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0080063

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J Maurer

P577

2013-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258639815

http://www.w3.org/2001/XMLSchema#string

P698

24244610

http://www.w3.org/2001/XMLSchema#string

P921

P932

3828213

http://www.w3.org/2001/XMLSchema#string